Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin Maintenance in TNBC
NCT04502680Phase 2Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jun 2021
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eribulin in triple-negative breast cancer (TNBC), sponsored by Jiangsu Provincial People's Hospital. Status: unknown.
02
Drugs
eribulin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04502680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04502680.